Progesterone Inhibits Mast Cell Secretion

Vasiadi, Magdalini; Kempuraj, Duraisamy; Boucher, William; Kalogeromitros, D.; Theoharides, Theoharis C.

doi:10.1177/039463200601900408

Cited by 88 publications

(62 citation statements)

References 39 publications

(47 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Estrogen receptors are also expressed on bladder [166][167][168] and lung [169,170] MCs. Human MCs also express progesterone [171,172] and testosterone [173] receptors, but their activation appears to have an inhibitory effect. Brain MCs are activated during estrus induction [174].…”

Section: Sex and Other Hormonesmentioning

confidence: 99%

Neuroendocrinology of the skin

Theoharides

Stewart

Taracanova

et al. 2016

Rev Endocr Metab Disord

View full text Add to dashboard Cite

The skin is considered the mirror of the soul and is affected by neurohormonal triggers, especially stress. Hair follicles, keratinocytes, mast cells, melanocytes, and sebocytes all express sex and stress hormones implicating them in a local "hypothalamic-pituitary-adrenal axis." In particular, the peptides corticotropin-releasing hormone (CRH) and neurotensin (NT) have synergistic action stimulating mast cells and are uniquely elevated in the serum of patients with skin diseases exacerbated by stress. Addressing the neurohormonal regulation of skin function could lead to new targets for effective treatment of inflammatory skin diseases.

show abstract

Section: Sex and Other Hormonesmentioning

confidence: 99%

Neuroendocrinology of the skin

Theoharides

Stewart

Taracanova

et al. 2016

Rev Endocr Metab Disord

View full text Add to dashboard Cite

show abstract

“…In this sense, the binding of estradiol to estrogen receptor-α on the membrane of MC at physiological concentrations has proven to support the synthesis and release of MC mediators in vitro [26]; conversely, progesterone and some antiestrogen drugs (e.g. tamoxifen) inhibit MC secretion and proliferation [27,28]. …”

Section: Discussionmentioning

confidence: 99%

Clinical Impact of Pregnancy in Mastocytosis: A Study of the Spanish Network on Mastocytosis (REMA) in 45 Cases

Matito

Álvarez‐Twose

Morgado

et al. 2011

Int Arch Allergy Immunol

View full text Add to dashboard Cite

Background: The impact of pregnancy on mast cell (MC)-related symptoms and newborn outcome in women with mastocytosis is not well described. We report a series of 30 women who had 45 pregnancies. Methods: Patients completed a specific questionnaire concerning MC mediator release symptoms graded according to their frequency to detect clinical changes occurring during pregestation and pregnancy as well as postpartum. Information about the medications received during pregnancy and labor and about newborn medical complications was also recorded. Results: Worsening of MC-related symptoms during pregnancy was observed in 10 cases (22%); additionally, 1 woman developed skin lesions as a manifestation of indolent systemic mastocytosis (ISM) within the third trimester of pregnancy. Conversely, 15 cases (33%) experienced clinical improvement during pregnancy, with a complete resolution of pregestational symptoms in 7 cases. MC mediator release symptoms intrapartum were observed in 5 cases (11%) without any fatal outcome. Newborn medical complications (e.g. prematurity, low birth weight, and respiratory distress) were detected in 7 infants (16%) who were all successfully managed with conservative measures. One infant developed cutaneous mastocytosis several years after birth. Conclusions: Mastocytosis has a heterogeneous clinical behavior during pregnancy: the profile of MC-related symptoms remained unchanged in half of the cases, while in the other half pregnant women experienced either an improvement or an exacerbation of the symptoms, with the manifestation of ISM during pregnancy in 1 case. To prevent potential life-threatening MC-related symptoms, adequate prophylactic antimediator therapy intrapartum should be systematically administered. The absence of both maternal and infant severe complications suggests that patients with nonaggressive categories of mastocytosis should not be advised against pregnancy.

show abstract

“…A single subcutaneous estrogen injection was shown to partially negate the natural tolerance process of IgE formation, and promote allergic sensitization in rodent models [34]. In contrast, tamoxifen, an estrogen receptor antagonist, has been shown to inhibit mast cell secretion [35]. Additionally, progesterone has been shown to inhibit secretion of rat peritoneal mast cells that had previously been stimulated [35].…”

Section: Estrogen's Effects On Atopic Dermatitismentioning

confidence: 99%

“…In contrast, tamoxifen, an estrogen receptor antagonist, has been shown to inhibit mast cell secretion [35]. Additionally, progesterone has been shown to inhibit secretion of rat peritoneal mast cells that had previously been stimulated [35].…”

Section: Estrogen's Effects On Atopic Dermatitismentioning

confidence: 99%

A Review of the Clinical and Immunologic Effects of Estrogen on Atopic Dermatitis

Murase¹

2015

OGIJ

View full text Add to dashboard Cite

One of the most important immunologic phenomena in pregnancy is a shift from T-helper 1 (Th1) to T-helper 2 (Th2) immunity. As a result, pregnancy is associated with an exacerbation of Th2 mediated diseases such as systemic lupus erythematosis, atopic dermatitis, and forms of pemphigus such as pemphigus vulgaris. To summarize the clinical and immunologic effects of estrogen as they relate to atopic dermatitis, we performed an English-language PubMed search of articles combining key terms including "atopic dermatitis," "atopic eruption of pregnancy," "estrogen," and "pregnancy." Estrogen appears to cause Th2 polarization and subsequent increase in Th2 cytokines. Pregnant women with atopic disease have greater numbers of Th2 cells producing IL-4 and IFN-gamma cytokines, and a decrease in the Th1 chemokine ratio. Effects of estrogen on Th17 cells vary depending on cell type. Estrogen stimulates mast cell proliferation and promotes allergic sensitization. Overall, atopic dermatitis tends to worsen during pregnancy, at least in part due to the effects of estrogen on the immune system. New advances in therapies will require an increased understanding of the immunopathology of AD, some of which may be learned by studying its unique course in pregnancy.

show abstract

Progesterone Inhibits Mast Cell Secretion

Cited by 88 publications

References 39 publications

Neuroendocrinology of the skin

Neuroendocrinology of the skin

Clinical Impact of Pregnancy in Mastocytosis: A Study of the Spanish Network on Mastocytosis (REMA) in 45 Cases

A Review of the Clinical and Immunologic Effects of Estrogen on Atopic Dermatitis

Contact Info

Product

Resources

About